Skip to main
BCAX

BCAX Stock Forecast & Price Target

BCAX Analyst Ratings

Based on 6 analyst ratings
Buy
Strong Buy 17%
Buy 50%
Hold 33%
Sell 0%
Strong Sell 0%

Bulls say

Bicara Therapeutics Inc. is positioned favorably due to its bifunctional therapy ficerafusp alfa, which has demonstrated superior overall response rates (ORR) compared to established treatments such as Keytruda in a comparable patient population. The combination of ficerafusp alfa with Keytruda resulted in a median progression-free survival (mPFS) of 9.9 months and a median overall survival (mOS) of 21.3 months, indicating a significant improvement over historical benchmarks in similar patient groups. Additionally, these promising results suggest the potential for ficerafusp alfa to address unmet needs in the treatment landscape for solid tumors, thereby enhancing Bicara Therapeutics's growth prospects and competitive position in the biopharmaceutical market.

Bears say

Bicara Therapeutics reported a net loss of $0.50 per share for the second quarter of 2025, consistent with prior estimates, indicating ongoing financial challenges. The company faces multiple risks including potential negative clinical results for its lead product, ficerafusp alfa, as well as delays in progressing the therapy into critical trials and achieving regulatory approvals, which could hinder future growth. Projections indicate a substantial full-year net loss of $2.27 per share for 2025, slightly improved from earlier estimates, but still reflecting persistent financial difficulties that may negatively impact investor confidence.

BCAX has been analyzed by 6 analysts, with a consensus rating of Buy. 17% of analysts recommend a Strong Buy, 50% recommend Buy, 33% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Bicara Therapeutics Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Bicara Therapeutics Inc (BCAX) Forecast

Analysts have given BCAX a Buy based on their latest research and market trends.

According to 6 analysts, BCAX has a Buy consensus rating as of Dec 24, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $24.84, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $24.84, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Bicara Therapeutics Inc (BCAX)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.